CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations CANVAS: Canagliflozin Reduces CV Events, but at Cost of Amputations
Pooled data from two CANVAS trials suggest that cardioprotection is likely a class effect with SGLT2 inhibitors, but it comes at the price of toe amputations.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Canagliflozin | Cardiology | Diabetes | Endocrinology | Health | Heart | Invokana | SGLT2 Inhibitors